Iambic Therapeutics’ Post

Unlock the secrets to revolutionizing oligonucleotide development with groundbreaking insights into the oligotherapeutics market. Discover why many oligos haven't reached the market and identify the bottlenecks slowing you down.  Whether you're among the 50% stuck in preclinical stages or still navigating discovery, this resource is packed with vital stats, tips, and strategies to propel you forward. Accelerate Your Research Today! https://hubs.la/Q02DBCX-0 #Pharma #PrecisionMedicine #siRNA #ASOs #mRNA

🔔 Taking part in the 9th RSC-BMCS Fragment-based Drug Discovery Meeting in Cambridge today and tomorrow? Stop by booth number 15 to speak with our NUVISAN experts Krzysztof Brzezinka and Martina Schaefer. 📅 In addition, don't miss Martina's presentation tomorrow at 11:30. She will present on the topic: Discovery of potent SOS1 inhibitors through complementary use of FBDD and HTS with insightful discussion to follow! #highthroughput #fragment #screening #KRAS #drugdiscovery

Kinase activity and drug interactions vary significantly under physiological conditions, often due to changes in ATP concentrations. With KinSight™ Kinome Profiling Services, you can achieve precise assessments of kinase inhibitory potency and selectivity at different ATP levels. Maximize your compound potency by performing profiling at the ATP Km concentration. Gain physiological insights by performing profiling at 1 mM ATP. Or, for significant potency and MOA insights, profile at both concentrations. Fulfill all your selectivity screening needs with KinSight. Discover how ATP context can enhance your target inhibition strategies and learn more about how you can leverage KinSight at all stages of the pre-clinical drug discovery process. https://lnkd.in/eyFV6Fun #kinaseprofiling #kinasepanel #kinomeprofiling #drugdevelopment #drugdiscovery

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions!

A well-written, comprehensive review on the inflammasome and inflammasome inhibitors from Nature Reviews Drug Discovery, prominently and, dare we say, fittingly, features RRx-001, since RRx-001 is the most advanced direct NLRP3 inflammasome inhibitor in clinical development. Read the review entitled “Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets,” here: https://lnkd.in/gvTUFiVv

In the most recent Spring Edition of Drug Discovery World, our CEO, Nicholas Siciliano, shares insights on the curative potential of CAR-T therapeutics and how Vittoria is helping shape the future of immunotherapy. To check out the full piece, read here: https://shorturl.at/bcrtN

Pharvaris announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results of deucrictibant as an oral preventative treatment for people living with HAE.  The study's primary endpoint measured the time-standardized number of investigator-confirmed HAE episodes during treatment. Participants receiving 40 mg of deucrictibant daily had an 84.5% reduction in monthly exacerbation rates compared to placebo (p=0.0008). Deucrictibant is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. By inhibiting bradykinin signaling through the bradykinin B2 receptor, deucrictibant has the potential to treat the clinical signs of an HAE attack and to prevent the occurrence of attacks. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gbPsm3q8 #Deucrictibant #HAE #bradykinin #bradykininB2receptor #Chemenu #buildingblocks

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions! https://lnkd.in/dN3yhYTs

Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector). This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/g2UMT3sS #Selatogrel #acutemyocardialinfarction #AMI #P2Y12 #ACT-246475 #buildingblocks 

Did you miss our recent webinar on "Efficiently Driving Protein-based #NMR Fragment Screening and Lead Discovery" ? Dr. Andrew “Dru” Namanja, Principal Research Scientist at AbbVie, explored the potency ranking methods involving both qualitative single-point ligand concentration (Q Score) and quantitative binding affinity (KD), and how the combined utility can be used successfully to drive a Fragment-Based Drug Discovery (#FBDD) campaign. If you missed any part of it, no worries! You can catch the recorded session here: https://lnkd.in/d9RfpXfs #dataautomation #FragmentBasedDrugDiscovery #Mnova #Mestrelab